This is an open label pilot study to assess the safety, tolerance and efficacy of hyperimmune egg yolks (IGX-CP) in patients with AIDS and cyrptosporidial diarrhea. Progress report and summary of findings: This study had been previously concluded. Analysis of findings is ongoing. Twenty-four subjects were enrolled and treated. 16 of the 24 evaluable subjects (56%) had a reduction in bowel movement frequency, and 6 subjects (38%) had a reduction in stool oocyst grade as compared with 1 subject (19%) in whom stool oocyst grade increased. No subject experienced sustained eradication of stool Cryptosporidium oocysts. While treatment was found to be safe, gastrointestinal symptoms (satiety) limited administration of IGX-CP at doses above 2.88 x10(6) AU/day.
Showing the most recent 10 out of 370 publications